Loading data for MBX — first visit, this takes a few seconds.

MBX Biosciences, Inc. (MBX)

NasdaqGS: MBX · 即時價格 · USD

63.00

-3.39 (-5.11%)

收盤價： Sep 02, 2026, 8:00 PM

提醒

Alert

股價、關鍵數字和最新消息，都在這一頁。

無可用資料

買價	46.36
市值	2.93B
營收 (ttm)	n/a
淨利（ttm）	-104M
	0.00
	-2.37
	n/a
	-15.4
P/B (ttm)	7.13
P/S (ttm)	0.00
財報日期	Nov 5, 2026

賣價	81.42
成交量	307,645
20 日平均成交量	760,841
開盤價	66.14
前收盤價	66.39
當日區間	62.99 - 66.14
52 週範圍	9.63 - 72.64
分析師	n/a
目標價	n/a
股利	n/a
除息日	n/a

關於 MBX

MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon...

[閱讀更多]

產業 Biotechnology

類股 Healthcare

IPO 日期 Sep 13, 2024

員工 63

證券交易所 NasdaqGS

股票代號 MBX

網站 https://mbxbio.com

完整的公司簡介

財務表現

MBX Biosciences 在 2025 年的營收為 0，較前一年的 0 增加 undefined%。淨利為 -86.97M，較前期增加 40.45%。

財務報表

財報驚奇

MBX Biosciences 已於 Aug 6, 2026 公布季度財報：

營收為 $0 低於預期 $0, 年增 NaN% 成長.
每股盈餘為 -0.78 低於預期 -0.19, 年增 -34.48% 下滑.

下次財報發布

MBX Biosciences, Inc. 的下次財報預計於 Nov 5, 2026, 開盤前。
分析師預估營收 ... 升級

價格為何變動

新聞動態

3 週前 · Barrons.com

UMH Properties and 4 More Stocks See Action From Activist Investors

Activists also report to the SEC on MBX Biosciences, Core Scientific, Gran Tierra Energy, and Shoulder Innovations.

1 月前 · Investor's Business Daily

Stock Market Checklist Helps Uncover Winners In Hot Biotechs

Use the IBD Stock Checklist to separate the wheat from the chaff in the stock market, specifically in the red-hot biotech sector.

2 月前 · Simply Wall St.

How Do MBX Biosciences’ (MBX) Phase 2 Results Reframe Its Long-Term Hypoparathyroidism Strategy?

MBX Biosciences recently reported full 12-week Phase 2 Avail trial results and one-year open-label extension data for once-weekly canvuparatide in adults with chronic hypoparathyroidism, showing highe...

2 月前 · InvestorsHub

MBX Biosciences Shares Fall Despite Positive One-Year Trial Results for Canvuparatide (MBX)

MBX Biosciences Inc. (NASDAQ:MBX) shares dropped 19.

2 月前 · BioPharma Dive

J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch

New data suggest Imaavy could be an effective treatment for autoimmune anemia. Elsewhere, Enliven detailed data for a Merck leukemia rival and MBX hyperparathyroidism drug hit its goal.

第 1 頁，共 2 頁

MBX Biosciences, Inc. (MBX)